Fish Oil for Cardiovascular Health: A Systematic Evidence Review

Fish oil likely helps triglycerides, and this is the most dependable lipid effect in the entire review. Across 17 trials, the average reduction was about 43.9 mg/dL, just shy of the 50 mg/dL threshold usually considered clearly meaningful, with a pooled effect that stayed positive despite varied populations and study designs (d 0.59, 95% CI 0.40 to 0.77; median d 0.40). That is the kind of change that could matter if triglycerides are elevated to begin with, and several individual trials showed this in familiar clinical units: about 46 mg/dL lower after 8 weeks in moderate hypertriglyceridemia, about 0.58 mmol/L lower over 3 months in NAFLD with hyperlipidemia, and about 0.4 to 0.5 mmol/L lower over 3 to 6 months in type 2 diabetes or similar risk states.^1819242935 Heterogeneity, measured by I-squared, was 72%, which means the size of benefit varied meaningfully across settings, but the prediction interval still stayed on the beneficial side of no effect. In plain terms, the triglyceride benefit looks real on average and is likely to show up in many, though not all, contexts.^110182434

Fish oil likely helps HDL cholesterol, but this signal is much less stable than the triglyceride story. The average rise was about 4.3 mg/dL, which is close to the 5 mg/dL threshold usually treated as noticeable, yet the pooled estimate was driven by very uneven studies and should not be read as a guaranteed HDL boost for everyone (pooled d 1.34, prediction interval crosses no effect; I-squared 92.5%). Some trials reported striking increases, especially in hemodialysis and renal disease populations, while others found only small or non-significant changes.¹⁴²⁴³² An I-squared above 90% means studies are not telling a single clean story. The likely explanation is that baseline lipid abnormality, kidney disease, comparator oil, and dose all changed the response enough that the average effect became unstable.

Fish oil does not appear to reliably improve LDL cholesterol, and this is where the popular reputation outruns the data. The average LDL change was only about 5.3 mg/dL against a 15 mg/dL threshold for clear clinical importance, and the confidence interval crossed no effect (pooled d 0.44, 95% CI -0.11 to 0.98; I-squared 78%). Some trials showed mild reductions, such as about 0.25 mmol/L over 12 weeks in hypertensive patients with abdominal obesity, while others showed no difference or even a modest rise, as seen in adolescents with elevated triglycerides.^14242932 The prediction interval also crossed no effect, which means benefit is not dependable across contexts. The practical takeaway is simple: fish oil is not a reliable LDL-lowering strategy.¹⁴²⁴²⁹

Advanced lipoprotein changes are promising but still early. In a small crossover trial of adults with moderate hypertriglyceridemia, 3.4 g/day EPA plus DHA reduced VLDL cholesterol by about 10 mg/dL, apo B by about 7 mg/dL, apo C-III by about 3 mg/dL, and slightly improved the apoB to apoA-I ratio over 8 weeks.¹⁸ Those directions make biological sense, because omega-3 fats reduce hepatic VLDL production and remnant burden, but most of these outcomes come from single small studies or very sparse replications. The combined atherogenic-lipoprotein signal was moderate in size overall but too inconsistent to treat as settled (combined d 0.42, I-squared 84%).²¹⁸³⁴

Cholesterol pattern claims beyond triglycerides remain weak. The total cholesterol to HDL ratio showed no meaningful effect in the one available trial, non-HDL cholesterol is too sparsely reported here to judge confidently, and HDL-related lipoprotein quality markers show only preliminary movement from small datasets.¹⁸³² Clinically, that leaves a fairly clean conclusion: fish oil looks useful when the problem is triglyceride-rich particles, not when the goal is broad correction of every cholesterol measure.

Fish oil probably does not produce a broad, dependable drop in hsCRP. Across five trials, the average change was about 0.9 mg/L, close to the 1.0 mg/L threshold often used as clinically meaningful, but the pooled confidence interval crossed no effect and the studies were highly inconsistent (pooled d 0.39, 95% CI -0.06 to 0.84; median d 0.02; I-squared 71.7%).^615202530 Large better-powered trials in healthy adults were clearly negative, including 18 weeks of 1.4 g/day with no CRP benefit and 2 to 4 years of 1 g/day with no hsCRP change in the VITAL ancillary cohort.²⁰³⁰ High I-squared here means the average looks more impressive than the typical study actually is. For most adults, hsCRP does not seem to be where fish oil reliably delivers.

IL-6 is more intriguing, but still exploratory. The pooled signal was positive and moderate in size (d 0.86, 95% CI 0.21 to 1.52), yet it came from only 206 participants across five heterogeneous studies, and the prediction interval crossed no effect widely (I-squared 78.6%).^1215222531 That means some studies showed meaningful suppression, especially exercise-related and small intervention models, while others showed little or none. For example, fish oil lowered exercise-induced IL-6 in a small young male trial after eccentric contractions and reduced IL-6 by about 10.9% in postmenopausal women training with resistance exercise, but did not significantly lower IL-6 in larger healthy-adult supplementation trials.^22311520

The most plausible interpretation is that fish oil may dampen specific inflammatory contexts more than baseline systemic inflammation. It may matter more when inflammation is triggered by metabolic stress, exercise-induced muscle damage, or certain disease states than when CRP and IL-6 are already low at baseline. That would explain why biomarker shifts show up in smaller mechanistic studies but disappear in broad healthier populations.^12202231

So the anti-inflammatory claim needs narrowing. Fish oil does not look like a general-purpose inflammation suppressant in routine blood testing, but early findings hint that it can influence selected cytokine pathways under the right conditions. That is a lead worth following, not a settled reason to take it for cardiovascular protection.^15202530

Fish oil does not appear to broadly stabilize cardiac rhythm in a clinically reliable way. The strongest evidence against that claim comes from postoperative atrial fibrillation, where a large, well-run trial found no benefit at all. In OPERA, postoperative AF occurred in 30.0% of fish-oil patients and 30.7% of placebo patients, with no reduction in sustained, symptomatic, treated, or early AF burden and no difference in time to first episode.⁹ That kind of null result is hard to explain away, because the sample was large enough to detect a realistic perioperative effect if one existed.

Resting heart rate changes are too small to matter much clinically. The summarized effect corresponds to about a 1.6 beats per minute reduction on average, which is far below the 5 bpm threshold generally considered noticeable or clinically relevant, and the pooled estimate was statistically uncertain despite very consistent studies (d 0.14, 95% CI -0.21 to 0.49; I-squared 0%).⁵⁷ Zero heterogeneity means the studies agree with each other, but what they agree on is essentially a tiny or null effect.

Heart rate variability, or HRV, remains an exploratory signal rather than a dependable rhythm benefit. HRV is a measure of beat-to-beat variation that often reflects autonomic balance. Some trials suggest improvement, especially at higher doses: 3.4 g/day increased RMSSD by 2.6 ms and total HRV power by about 21% over 8 weeks in adults with moderate hypertriglyceridemia, and a DHA-rich 6 g/day regimen lowered the LF:HF ratio over 12 weeks.¹¹⁵ But the pooled HRV evidence is very weak overall because there are only three small trials, the studies disagree substantially, and the prediction interval is extremely wide (pooled d 0.70, I-squared 75.8%, prediction interval crosses no effect broadly).⁵¹¹¹⁷ That means some settings may benefit, but the average effect is not stable enough to rely on.

The broader arrhythmia-prevention case stays weak. Summarized evidence for atrial fibrillation control, sudden-death related endpoints, and implantable defibrillator shocks is mostly null or trivial in size, even when confidence in the null is moderate.⁹ Taken together, these findings sharply limit the claim that fish oil broadly improves electrical stability of the heart.

This is one of the clearest places where null findings are valuable. Fish oil may nudge vascular risk factors, but the current analysis does not support using it with the expectation that it will prevent atrial fibrillation or meaningfully stabilize heart rhythm in most adults.⁵⁹¹¹